Dapagliflozin

Cada, Dennis J.; Levien, Terri; Baker, Danial E.

doi:10.1310/hpj4907-647

Cited by 5 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(39,40) The use of SGLT-2 inhibitors, including dapagliflozin, in pregnancy and in the breastfeeding period is not recommended. (39,41) Future studies in this field should focus on assessing the acceptability and effectiveness of metformin in the immediate postnatal period, as metformin is a safe drug to use and potentially can reduce diabetes risk in the early postpartum period. Based on the evidence discussed in this section there is a notable gap in research in pharmacological treatment in the first years after a GDM pregnancy.…”

Section: Pharmacological Interventions To Prevent Diabetes Developmentmentioning

confidence: 99%

Strategies to prevent Type 2 Diabetes in the postnatal period in women with history of Gestational Diabetes

Bolou Angeliki,

Gourounti Kleanthi

2024

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

This literature review emphasizes the critical need for focused interventions to prevent Type 2 Diabetes (T2D) in the postnatal period, particularly for women with a history of Gestational Diabetes Mellitus (GDM). GDM poses a substantial risk, increasing the likelihood of T2D development by 11-fold later in life. With 14% of pregnancies worldwide affected by GDM, the escalating global T2D rates underscore the urgency for targeted postnatal strategies. Current interventions, such as those modelled after the Diabetes Prevention Program (DPP) and the Mediterranean Diet, show promise in reducing T2D risk by over 50%, yet challenges like low engagement persist. To address these complexities, future research should prioritize developing acceptable postnatal interventions, incorporating peer support, addressing barriers, and employing randomized controlled trials with larger participant cohorts. The multidimensional approach involves lifestyle modifications, dietary changes, behaviour change strategies, and exploration of pharmacological options, collectively contributing to a substantial reduction in the long-term T2D risk for women with a history of GDM.

show abstract

Section: Pharmacological Interventions To Prevent Diabetes Developmentmentioning

confidence: 99%

Strategies to prevent Type 2 Diabetes in the postnatal period in women with history of Gestational Diabetes

Bolou Angeliki,

Gourounti Kleanthi

2024

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

show abstract

“…Flozins are primarily recommended for obese patients at high risk of hypoglycemia who cannot tolerate metformin or who require combination therapy. Due to their cardioprotective and nephroprotective effects, they are increasingly used for type 2 diabetic patients with additional cardiovascular or nephrological burden [ 102 , 103 , 104 ]. Other drugs in this group registered in Europe for the treatment of type 2 diabetes in monotherapy or combination treatment are canagliflozin (Invokana ® , 2013) [ 105 ], empagliflozin (Jardiance ® , 2014) [ 106 ], and ertugliflozin (Steglatro ® , 2017) [ 107 ], and a drug registered for the treatment of type 1 diabetes as a supplement to insulin therapy is sotagliflozin (Zynquista ® , 2019) [ 108 ].…”

Section: Sodium-glucose Cotransporter-2 (Sglt2) Inhibitorsmentioning

confidence: 99%

“…In contrast, the remaining 10% of filtered glucose is reabsorbed by the SGLT-1 cotransporters, with high affinity and low capacity, present in the S3 segment of the PCT. Glucose exits these tubular cells back into circulation through the GLUT2 (for cells with SGLT2) and GLUT1 (for cells with SGLT1) transporters in the basolateral membrane [ 104 , 119 , 120 ].…”

Section: Sodium-glucose Cotransporter-2 (Sglt2) Inhibitorsmentioning

confidence: 99%

The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins

Bodnar,

Mazurkiewicz,

Chwalba

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Heart failure (HF) is a multifactorial clinical syndrome involving many complex processes. The causes may be related to abnormal heart structure and/or function. Changes in the renin-angiotensin-aldosterone system, the sympathetic nervous system, and the natriuretic peptide system are important in the pathophysiology of HF. Dysregulation or overexpression of these processes leads to changes in cardiac preload and afterload, changes in the vascular system, peripheral vascular dysfunction and remodeling, and endothelial dysfunction. One of the important factors responsible for the development of heart failure at the cellular level is oxidative stress. This condition leads to deleterious cellular effects as increased levels of free radicals gradually disrupt the state of equilibrium, and, as a consequence, the internal antioxidant defense system is damaged. This review focuses on pharmacotherapy for chronic heart failure with regard to oxidation–reduction metabolism, with special attention paid to the latest group of drugs, SGLT2 inhibitors—an integral part of HF treatment. These drugs have been shown to have beneficial effects by protecting the antioxidant system at the cellular level.

show abstract

Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks

Perry

Shulman

2020

Journal of Biological Chemistry

View full text Add to dashboard Cite

In a healthy person, the kidney filters nearly 200 g of glucose per day, almost all of which is reabsorbed. The primary transporter responsible for renal glucose reabsorption is sodium-glucose cotransporter-2 (SGLT2). Based on the impact of SGLT2 to prevent renal glucose wasting, SGLT2 inhibitors have been developed to treat diabetes and are the newest class of glucose-lowering agents approved in the U.S. By inhibiting glucose reabsorption in the proximal tubule, these agents promote glycosuria, thereby reducing blood glucose concentrations and often resulting in modest weight loss. Recent work in humans and rodents has demonstrated that the clinical utility of these agents may not be limited to diabetes management: SGLT2 inhibitors have also shown therapeutic promise in improving outcomes in heart failure, atrial fibrillation, and, in preclinical studies, certain cancers. Unfortunately, these benefits are not without risk: SGLT2 inhibitors predispose to euglycemic ketoacidosis in those with type 2 diabetes, and largely for this reason, are not approved to treat type 1 diabetes. The mechanism for each of the beneficial and the harmful effects of SGLT2 inhibitors – with the exception of their effect to lower plasma glucose concentrations – is an area of active investigation. In this review, we discuss the mechanisms by which these drugs cause euglycemic ketoacidosis, hyperglucagonemia and stimulate hepatic gluconeogenesis as well as their beneficial effects in cardiovascular disease and cancer. In so doing, we aim to highlight the crucial role for selecting patients for SGLT2 inhibitor therapy and highlight several crucial questions that remain unanswered.

show abstract

Dapagliflozin

Cited by 5 publications

References 34 publications

Strategies to prevent Type 2 Diabetes in the postnatal period in women with history of Gestational Diabetes

Strategies to prevent Type 2 Diabetes in the postnatal period in women with history of Gestational Diabetes

The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins

Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks

Contact Info

Product

Resources

About